Febuxostat, a Urate-Lowering Drug Bridging From Adults to Pediatrics; A Brief Report

IF 3.2 4区医学 Q2 PHARMACOLOGY & PHARMACY

Clinical therapeutics Pub Date : 2025-03-01 DOI:10.1016/j.clinthera.2025.01.017

Toktam Faghihi PharmD , Farahnak Assadi MD

{"title":"Febuxostat, a Urate-Lowering Drug Bridging From Adults to Pediatrics; A Brief Report","authors":"Toktam Faghihi PharmD , Farahnak Assadi MD","doi":"10.1016/j.clinthera.2025.01.017","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Febuxostat, a nonpurine selective inhibitor of xanthine oxidase has elucidated an effective urate-lowering in adults. However, data on febuxostat utility in children is limited. The present study summarizes the current knowledge on the efficacy and safety of febuxostat in children with hyperuricemia.</div></div><div><h3>Methods</h3><div>We searched PubMed, Google Scholar, Embase, and Web of Science from inception to September 2024 for studies assessing febuxostat or comparing febuxostat with allopurinol in children and adolescents with hyperuricemia with diverse etiologies. Randomized controlled trials, prospective observational, and systematic reviews, meta-analyses, and retrospective studies were included.</div></div><div><h3>Findings</h3><div>Search results illuminated three studies assessing febuxostat in children with hyperuricemia of different etiologies; including tumor lysis syndrome (TLS), asymptomatic hyperuricemia, and gout. An open-label observational study and one-retrospective study assessed febuxostat efficacy for asymptomatic hyperuricemia and gout, respectively. There was one retrospective study that compared febuxostat to allopurinol for TLS prevention.</div></div><div><h3>Implications</h3><div>Febuxostat is a promising medication that is effective in attaining the desired outcomes in children with hyperuricemia. However, existing evidence does not permit any conclusion regarding the comparative efficacy and safety of febuxostat with allopurinol in children. Future randomized clinical trials evaluating its effectiveness and safety are needed.</div></div>","PeriodicalId":10699,"journal":{"name":"Clinical therapeutics","volume":"47 5","pages":"Pages e33-e36"},"PeriodicalIF":3.2000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0149291825000311","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

Febuxostat, a nonpurine selective inhibitor of xanthine oxidase has elucidated an effective urate-lowering in adults. However, data on febuxostat utility in children is limited. The present study summarizes the current knowledge on the efficacy and safety of febuxostat in children with hyperuricemia.

Methods

We searched PubMed, Google Scholar, Embase, and Web of Science from inception to September 2024 for studies assessing febuxostat or comparing febuxostat with allopurinol in children and adolescents with hyperuricemia with diverse etiologies. Randomized controlled trials, prospective observational, and systematic reviews, meta-analyses, and retrospective studies were included.

Findings

Search results illuminated three studies assessing febuxostat in children with hyperuricemia of different etiologies; including tumor lysis syndrome (TLS), asymptomatic hyperuricemia, and gout. An open-label observational study and one-retrospective study assessed febuxostat efficacy for asymptomatic hyperuricemia and gout, respectively. There was one retrospective study that compared febuxostat to allopurinol for TLS prevention.

Implications

Febuxostat is a promising medication that is effective in attaining the desired outcomes in children with hyperuricemia. However, existing evidence does not permit any conclusion regarding the comparative efficacy and safety of febuxostat with allopurinol in children. Future randomized clinical trials evaluating its effectiveness and safety are needed.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical therapeutics 医学-药学

CiteScore

6.00

自引率

3.10%

发文量

154

审稿时长

9 weeks

期刊介绍： Clinical Therapeutics provides peer-reviewed, rapid publication of recent developments in drug and other therapies as well as in diagnostics, pharmacoeconomics, health policy, treatment outcomes, and innovations in drug and biologics research. In addition Clinical Therapeutics features updates on specific topics collated by expert Topic Editors. Clinical Therapeutics is read by a large international audience of scientists and clinicians in a variety of research, academic, and clinical practice settings. Articles are indexed by all major biomedical abstracting databases.